Reassessing Drug Inspection Targets: FDA Updates Internal Policy for Risk-Based Site Selection Model | Morgan Lewis - As Prescribed
In a continuing effort to improve the quality system effectiveness of human drug manufacturing sites, FDA revised MAPP 5014.1, Understanding CDER’s Risk-Based Site Selection Model (Site...
Office Of Pharmaceutical Quality Office Of Quality Surveillance Based Site Selection Model Site Selection Drug Evaluation Pharmaceutical Quality
Source: jdsupra.com